[go: up one dir, main page]

AR132276A1 - Complejo de conjugación - Google Patents

Complejo de conjugación

Info

Publication number
AR132276A1
AR132276A1 ARP240100787A ARP240100787A AR132276A1 AR 132276 A1 AR132276 A1 AR 132276A1 AR P240100787 A ARP240100787 A AR P240100787A AR P240100787 A ARP240100787 A AR P240100787A AR 132276 A1 AR132276 A1 AR 132276A1
Authority
AR
Argentina
Prior art keywords
binding partner
ligand
target cell
molecule
active substance
Prior art date
Application number
ARP240100787A
Other languages
English (en)
Inventor
Satoru Matsumoto
Eriya KENJO
Yutaka Nishimoto
Tomoya Takenaka
Yumiko Ishii
Joseph Sean Harrison
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR132276A1 publication Critical patent/AR132276A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nanotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un complejo para administrar una sustancia activa, que comprende un vehículo de administración para la sustancia activa y un ligando específico para una célula diana, mediante la adhesión del ligando a la superficie exterior del vehículo de administración, en donde el vehículo de administración está compuesto por una molécula de anclaje, un primer socio de unión está unido covalentemente al ligando en una proporción de 1 - 4 moléculas del primer socio de unión por una molécula del ligando; un segundo socio de unión está unido covalentemente a la molécula de anclaje, de modo que el segundo socio de unión está inmovilizado al vehículo de administración; y el primer socio de unión está unido covalentemente al segundo socio de unión. Reivindicación 1: Complejo para administrar una sustancia activa, caracterizado porque comprende un vehículo de administración de la sustancia activa y un ligando específico de una célula diana, el ligando se añade a la superficie exterior del vehículo de administración, en donde el vehículo de administración está formado por una molécula de anclaje, un primer socio de unión está unido covalentemente al ligando en una proporción de 1 - 4 moléculas del primer socio de unión por una molécula del ligando; un segundo socio de unión está unido covalentemente a la molécula de anclaje, de modo que el segundo socio de unión está inmovilizado al vehículo de administración; y el primer socio de unión está unido covalentemente al segundo socio de unión. Reivindicación 13: Un medicamento caracterizado porque comprende el complejo de acuerdo con la reivindicación 12. Reivindicación 14: Un método para producir el complejo de acuerdo con la reivindicación 1, caracterizado porque comprende: (1) una etapa de unir covalentemente el primer socio de unión al ligando en una proporción de 1 - 4 moléculas del primer socio de unión por una molécula del primer socio de unión; (2) una etapa de unión covalente del segundo socio de unión a la molécula de anclaje; y (3) una etapa de unión del primer socio de unión al segundo socio de unión mediante una reacción química en una proporción de una molécula del segundo socio de unión por una molécula del primer socio de unión. Reivindicación 24: Una composición para administrar la sustancia activa a la célula diana caracterizada porque comprende el complejo de acuerdo con la reivindicación 1. Reivindicación 35: Un método para activar y/o proliferar la célula diana, caracterizado porque comprende: una etapa de poner en contacto el complejo de acuerdo con la reivindicación 1 y una población celular que comprende la célula diana, donde el complejo comprende al menos un ligando específico de la célula diana. Reivindicación 48: Un método para administrar la sustancia activa dentro de la célula diana, caracterizado porque comprende: una etapa de puesta en contacto del complejo de acuerdo con la reivindicación 1 y una población celular que comprende la célula diana, en donde la sustancia activa no incluye ningún ácido nucleico que codifique un CAR ni un TCR. Reivindicación 62: Un medicamento caracterizado porque comprende la célula diana de acuerdo con la reivindicación 61.
ARP240100787A 2023-04-07 2024-04-03 Complejo de conjugación AR132276A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363494889P 2023-04-07 2023-04-07

Publications (1)

Publication Number Publication Date
AR132276A1 true AR132276A1 (es) 2025-06-11

Family

ID=90825510

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100787A AR132276A1 (es) 2023-04-07 2024-04-03 Complejo de conjugación

Country Status (3)

Country Link
AR (1) AR132276A1 (es)
TW (1) TW202449142A (es)
WO (1) WO2024210160A1 (es)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
JP5777519B2 (ja) 2008-10-09 2015-09-09 テクミラ ファーマシューティカルズ コーポレイション 改良されたアミノ脂質および核酸の送達方法
CA2743136C (en) 2008-11-10 2019-02-26 Muthiah Manoharan Novel lipids and compositions for the delivery of therapeutics
AU2011261247B2 (en) 2010-06-03 2016-08-25 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
NZ700075A (en) 2012-02-24 2016-05-27 Protiva Biotherapeutics Inc Trialkyl cationic lipids and methods of use thereof
TW201408625A (zh) 2012-07-06 2014-03-01 Kyowa Hakko Kirin Co Ltd 陽離子性脂質
EP2711418B1 (en) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
WO2014153114A1 (en) 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
TW201534578A (zh) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
CN105555757A (zh) 2013-07-23 2016-05-04 普洛体维生物治疗公司 用于递送信使rna的组合物和方法
ES2986054T3 (es) 2013-11-18 2024-11-08 Arcturus Therapeutics Inc Lípido catiónico ionizable para el suministro de ARN
PT3766916T (pt) 2014-06-25 2022-11-28 Acuitas Therapeutics Inc Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
CA2955154C (en) 2014-07-21 2023-10-31 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
KR101882634B1 (ko) 2014-08-07 2018-07-26 다케다 야쿠힝 고교 가부시키가이샤 양이온성 지질
TWI699354B (zh) 2014-12-26 2020-07-21 日商衛材R&D企管股份有限公司 陽離子性脂質
ES3031941T3 (en) 2015-05-26 2025-07-14 Univ Ramot Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes
CN105636090A (zh) 2015-06-30 2016-06-01 宇龙计算机通信科技(深圳)有限公司 业务检测方法及业务检测系统、终端和基站
IL315940A (en) 2015-07-28 2024-11-01 Univ Pennsylvania Altered monocytes/macrophages expressing chimeric antigen receptors and their uses
PT3368507T (pt) 2015-10-28 2023-02-07 Acuitas Therapeutics Inc Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
EP3397613A1 (en) 2015-12-30 2018-11-07 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
CN118512583A (zh) 2017-12-27 2024-08-20 武田药品工业株式会社 含核酸脂质纳米粒子及其用途
KR102589314B1 (ko) 2017-12-28 2023-10-13 다케다 야쿠힝 고교 가부시키가이샤 양이온성 지질
CN112533893B (zh) 2018-08-10 2023-12-22 武田药品工业株式会社 阳离子性脂质
MX2021004357A (es) 2018-10-18 2021-05-31 Takeda Pharmaceuticals Co Metodo para la activacion y proliferacion de las celulas t.
US20230001009A1 (en) 2019-12-04 2023-01-05 The Trustees Of The University Of Pennsylvania Nanoparticle compositions and methods of use

Also Published As

Publication number Publication date
TW202449142A (zh) 2024-12-16
WO2024210160A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
Wang et al. Antifouling peptide hydrogel based electrochemical biosensors for highly sensitive detection of cancer biomarker HER2 in human serum
CN108430458B (zh) 还原和氧化的多糖及其使用方法
CN101918554B (zh) 多糖/双链rna复合物
Moosa et al. Applications of nanodiamonds in drug delivery and catalysis
Abune et al. Aptamer‐functionalized hydrogels: An emerging class of biomaterials for protein delivery, cell capture, regenerative medicine, and molecular biosensing
Zandieh et al. Transition metal-mediated DNA adsorption on polydopamine nanoparticles
Barker et al. Biodegradable DNA-enabled poly (ethylene glycol) hydrogels prepared by copper-free click chemistry
EP3801025A1 (en) Composition and methods of controllable co-coupling polypeptide nanoparticle delivery system for nucleic acid therapeutics
Wu et al. DNA hydrogels and their derivatives in biomedical engineering applications
JP2016168062A (ja) Ｄｎａ−細胞コンジュゲート
CN101702917A (zh) 一种调节核酸分子活性的方法
Kausaite‐Minkstimiene et al. An Amperometric Glucose Biosensor Based on Poly (Pyrrole‐2‐Carboxylic Acid)/Glucose Oxidase Biocomposite
Ross et al. Effects of molecular weight and loading on matrix metalloproteinase-2 mediated release from poly (ethylene glycol) diacrylate hydrogels
Liu et al. Aptamer-incorporated hydrogels for visual detection, controlled drug release, and targeted cancer therapy
US20210130864A1 (en) Programmed dna-driven self-assembled rna hydrogel
CN104558107B (zh) 酶响应性的两亲性多肽和药物载体及其制备方法
CN114438088A (zh) 一种溶酶体靶向的核酸嵌合体的制备及应用
Chen et al. An ion-gating multinanochannel system based on a copper-responsive self-cleaving DNAzyme
CL2024001920A1 (es) Conjugación de anticuerpos en sitios específicos y su uso
AR132276A1 (es) Complejo de conjugación
Tang et al. Assembly of rolling circle amplification‐produced ultralong single‐stranded DNA to construct biofunctional DNA materials
Kusakabe et al. Gene 4 DNA primase of bacteriophage T7 mediates the annealing and extension of ribo-oligonucleotides at primase recognition sites
CN108611348B (zh) 一种树枝状dna组装体的制备方法及其用途
CN104861177A (zh) 具有凝血酶响应性溶栓能力的水凝胶材料以及制备方法
Peng et al. Rolling circle amplification with an expanded genetic alphabet (ExRCA) generates DNA materials incorporating additional building blocks for enhanced programmable functionalization